The antidepressant-like effects of delta-opiod receptor agonists

Molecular Interventions

Volumn 6, Issue 3, 2006, Pages 162-169

  Jutkiewicz, Emily M ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [2 BENZYL 3 (PROPIONYLTHIO)PROPIONAMIDO] 5 METHYLBENZOIC ACID; 4 [ALPHA (4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 HYDROXYBENZYL] N,N DIETHYLBENZAMIDE; 4 [ALPHA (4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 METHOXYBENZYL] N,N DIETHYLBENZAMIDE; AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; DELTA OPIATE RECEPTOR AGONIST; ENDORPHIN; ENKEPHALIN; ENKEPHALINASE INHIBITOR; FLUOXETINE; FLUVOXAMINE; KAPPA OPIATE RECEPTOR AGONIST; MIDAZOLAM; MODAFINIL; MORPHINE; MU OPIATE RECEPTOR AGONIST; N [2 BENZYL 3 [(HYDROXYAMINO)CARBONYL]PROPIONYL]PHENYLALANINE; NALTRINDOLE; NORADRENALIN; RB 38 B; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; UNCLASSIFIED DRUG; VENLAFAXINE;

ANALGESIA; ANTINOCICEPTION; BEHAVIORAL SCIENCE; CONVULSION; DEPRESSION; DOSE RESPONSE; DRUG ACTIVATION; DRUG EFFECT; DRUG STRUCTURE; EMOTION; HUMAN; LOCOMOTION; MOOD; NEUROPROTECTION; NONHUMAN; REVIEW; SEIZURE;

ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; CONVULSANTS; DEPRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; RECEPTORS, OPIOID, DELTA;

EID: 33745698596     PISSN: 15340384     EISSN: None     Source Type: Journal    
DOI: 10.1124/mi.6.3.7     Document Type: Review

References (69)

1. Baghai, T.C., Möller, H.-J., and Rupprecht, R Recent progress in pharmacological and non-pharmacological treatment options of major depression. Curr. Pharm. Des. 12, 503-515 (2006).
2. Djurovic, D., Milic-Aškrabic, J., and Majkic-Singh, N. Serum β-endorphin level in patients with depression on fluvoxamine. Farmaco 54, 130-133 (1999).
3. Kline, N.S., Li, C.H., Lehmann, H.E., Lajtha, A., Laski, E., and Cooper, T. Beta-endorphin-induced changes in schizophrenic and depressed patients. Arch. Gen. Psychiatry 34, 1111-1113 (1977).
4. Gerner, R.H., Catlin, D.H., Gorelick, D.A., Hui, K.K., and Li, C.H. Beta-endorphin. Intravenous infusion causes behavioral change in psychiatric inpatients. Arch. Gen. Psychiatry 37, 642-647 (1980).
5. Gorelick, D.A., Catlin, D.H., and Gerner, R.H. Beta-endorphin studies in psychiatric patients. Mod. Probl. Pharmacopsychiatry 17, 236-245 (1981).
6. Catlin, D.H., Gorelick, D.A., Gerner, R.H., Hui, K.K., and Li, C.H. Clinical effects of beta-endorphin infusions. Adv. Biochem. Psychopharmacol. 22, 465-472 (1980).
7. Fink, M., Simeon, J., Itil, T.M., and Freedman, A.M. Clinical antidepressant activity of cyclazocine - a narcotic antagonist. Clin. Pharmacol. Ther. 11, 41-48 (1970).
8. Emrich, H.M., Vogt, P., and Herz, A. Possible antidepressive effects of opioids: Action of buprenorphine. Ann. N.Y. Acad. Sci. 398, 108-112 (1982).
9. Bodkin, J.A., Zornberg, G.L., Lukas, S.E., and Cole, J.O. Buprenorphine treatment for refractory depression. J. Clin. Psychopharmacol. 15, 49-57 (1995).
10. Stoll, A.L. and Rueter, S. Treatment augmentation with opiates in severe and refractory major depression. Am. J. Psychiatry 156, 2017 (1999).
11. De Gandarias, J.M., Irazusta, J., Varona, A., Gil, J., Fernandez, D., and Casis, L. Effect of imipramine on enkephalin-degrading peptidases. Eur. Neuropsychopharmacol. 9, 493-499 (1999).
12. Besson, A., Privat, A.M., Eschalier, A., and Fialip, J. Dopaminergic and opioidergic mediations of tricyclic antidepressants in the learned helplessness paradigm. Pharmacol. Biochem. Behav. 64, 541-548 (1999).
13. Vilpoux, C., Carpentier, C., Leroux-Nicollet, I., Naudon, L., and Costentin, J. Differential effects of chronic antidepressant treatments on μ- and δ-opioid receptors in rat brain. Eur. J. Pharmacol. 443, 85-93 (2002).
14. Emrich, H.M., Hollt, V., Kissling, M., Fischler, M., Laspe, H., Heinemann, H., Zerssen, D.V., and Herz, A. Beta-endorphin-like immunoreactivity in cerebrospinal fluid and plasma of patients with schizophrenia and other neuropsychiatric disorders. Pharmakopsychiatr. Neuropsychopharmakol. 12, 269-276 (1979).
15. Inturrisi, C.E., Alexopoulos, G., Lipman, R., Foley, K., and Roosier, J. Beta-endorphin immunoreactivity in the plasma of psychiatric patients receiving electroconvulsive treatment. Ann. N.Y. Acad. Sci. 398, 413-423 (1982).
16. Filliol, D., Ghozland, S., Chluba, J. et al. Mice deficient for δ- and μ-opioid receptors exhibit opposing alterations of emotional responses. Nature 25, 195-200 (2000). These authors were the first to show that deletion of the delta-opioid receptor produces pro-depressive-like behaviors in mice.
17. Kastin, A.J., Scollan, E.L., Ehrensing, R.H., Schally, A.V., and Coy, D.H. Enkephalin and other peptides reduce passiveness. Pharmacol. Biochem. Behav. 9, 515-519 (1978).
18. Tejedor-Real, P., Micó, J.A., Maldonado, R., Roques, B.P., and Gibert-Rahola, J. Implication of endogenous opioid system in the learned helplessness model of depression. Pharmacol. Biochem. Behav. 52, 145-152 (1995).
19. Tejedor-Real, P., Micó, J.A., Smadja, C., Maldonado, R., Roques, B.P., and Gibert-Rahola, J. Involvement of δ-opioid receptors in the effects induced by endogenous enkephalins on learned helplessness model. Eur. J. Pharmacol. 354, 1-7 (1998).
20. Torregrossa, M.M., Jutkiewicz, E.M., Mosberg, H.I., Balboni, G., Watson, S.J., and Woods, J.H. Peptidic delta opioid receptor agonists produce antidepressant-like effects in the forced swim test and regulate BDNF mRNA expression in rats. Brain Res. 1069, 172-181 (2006).
21. Tejedor-Real, P., Micó, J.A., Maldonado, R., Roques, B.P., and Gibert-Rahola, J. Effect of mixed (RB 38A) and selective (RB 38B) inhibitors of enkephalin degrading enzymes on a model of depression in the rat. Biol. Psychiatry 34, 100-107 (1993).
22. Kita, A., Imano, K., Seto, Y., Yakuo, I., Deguchi, T., and Nakamura, H. Antinociceptive and antidepressant-like profiles of BL-2401, a novel enkephalinase inhibitor, in mice and rats. Jpn. J. Pharmacol. 75, 337-346 (1997).
23. Baamonde, A., Daugé, V., Ruiz-Gayo, M., Fulga, I.G., Turcaud, S., Fournié-Zaluski, M.C., and Roques, B.P. Antidepressant-type effects of endogenous enkephalins protected by systemic RB 101 are mediated by opioid δ and dopamine D1 receptor stimulation. Eur. J. Pharmacol. 216, 157-166 (1992). This paper indicates for the first time that the delta-opioid receptor is involved in the antidepressant-like effects of enkephalinase inhibitors.
24. Cordonnier, L., Sanchez, M., Roques, B.P., and Noble, F. Facilitation of enkephalins-induced delta-opioid behavioral responses by chronic amisulpride treatment. Neuroscience 135, 1-10 (2005).
25. Jutkiewicz, E.M., Torregrossa, M.M., Sobczk-Kojiro, K., Mosberg, H.I., Folk, J.E., Rice, K.C., Watson, S.J., and Woods, J.H. Behavioral and neurobiological effects of the enkephalinase inhibitor RB101 relative to its antidepressant effects. Eur. J. Pharmacol. 531, 151-159 (2006).
26. Noble, F., Soleilhac, J.M., Soroca-Lucas, E., Turcaud, S., Fournié-Zaluski, M.C., and Roques, B.P. Inhibition of the enkephalin-metabolizing enzymes by the first systemically active mixed inhibitor prodrug RB 101 induces potent analgesic responses in mice and rats. J. Pharmacol. Exp. Ther. 261, 181-190 (1992).
27. Broom, D.C., Jutkiewicz, E.M., Folk, J.E., Traynor, J.R., Rice, K.C., and Woods, J.H. Nonpeptidic delta-opioid receptor agonists reduce immobility in the forced swim assay in rats. Neuropsychopharmacology 26, 744-755 (2002). This was the first description of the antidepressantlike effects of nonpeptidic delta-opioid agonists as compared with typical antidepressants.
28. Jutkiewicz, E.M., Rice, K.C., Woods, J.H., and Winsauer, P.J. The effects of the delta-opioid receptor agonist SNC80 on learning relative to its antidepressant-like effects in rats. Behav. Pharmacol. 14, 509-516 (2003).
29. Perrine, S.A., Page, M.E., Gould, T.J., Cowan, A., and Unterwald, E.M. Behavioral effects of delta opioid ligands in an elevated plus maze and forced swim test. The Pharmacologist 45, 132. MAPS Abstract (2003).
30. Saitoh, A. and Kamei, J. Abstract O VIII-1. Antidepressant- and anxiolytic-like effect of SNC80, a selective delta-opioid receptor agonist, in olfactory bulbectomized rat model of depression. INRC 2004 meeting/Kyoto Japan. July 18-23. p. 45. (2004).
31. Hirose, N., Saitoh, A., and Kamei, J. Effects of SNC80 on the exploratory behavior of olfactory bulbectomized mice in the hole-board test. INRC Annapolis, MD July 10-15. Abstract T17 (2005).
32. Comer, S.D., Hoenicke, E.M., Sable, A.I., McNutt, R.W., Chang, K.J., De Costa, B.R., Mosberg, H.I., and Woods, J.H. Convulsive effects of systemic administration of the delta opioid agonist BW373U86 in mice. J. Pharmacol. Exp. Ther. 267, 888-895 (1993). This is one of the first papers fully characterizing the convulsive effects of a nonpeptidic delta-opioid agonist BW373U86.
33. Jutkiewicz, E.M., Eller, E.B., Folk, J.E., Rice, K.C., Traynor, J.R., and Woods, J.H. Delta-opioid agonists: Differential efficacy and potency of SNC80, its 3-OH (SNC86) and 3-desoxy (SNC162) derivatives in Sprague-Dawley rats. J. Pharmacol. Exp. Ther. 309, 173-181 (2004).
34. Broom, D.C., Jutkiewicz, E.M., Folk, J.E., Traynor, J.R., Rice, K.C., and Woods, J.H. Convulsant activity of a nonpeptidic delta-opioid receptor agonist is not required for antidepressant-like effects. Psychopharmacology 164, 42-48 (2002). This was the first paper to demonstrate that the convulsive effects are not required for the antidepressant-like effects of delta-opioid agonists.
35. Jutkiewicz, E.M., Baladi, M.G., Rice, K.C., and Woods, J.H. The convulsive and electroencephalographic changes produced by nonpeptidic delta-opioid agonists in rats: Comparison with pentylenetetrazol. J. Pharmacol. Exp. Ther. 317, 1337-1348 (2006). This is the first article to characterize fully the epileptogenic effects of nonpeptidic deltaopioid agonists.
36. Torregrossa, M.M., Isgor, C., Folk, J.E., Rice, K.C., Watson, S.J., and Woods, J.H. The delta-opioid receptor agonist (+)BW373U86 regulates BDNF mRNA expression in rats. Neuropsychopharmacology 29, 649-659 (2004). This paper demonstrated for the first time that nonpeptidic delta-opioid agonists increase BDNF mRNA expression.
37. Jutkiewicz, E.M., Kaminsky, S., Rice, K.C., and Woods, J.H. Differential behavioral tolerance to the δ-opioid agonist SNC80 ([(+)-4-[(αR)- α-[(2S,5R)-2,5-dimethyl-4-(2-propenyl)-1-piperazinyl]-(3-methyoxyphenyl) methyl]-N,N-diethylbenzamide) in Sprague-Dawley rats. J. Pharmacol. Exp. Ther. 315, 414-422 (2005).
38. Jutkiewicz, E.M., Rice, K.C., Traynor, J.R., and Woods, J.H. Separation of the convulsions and antidepressant-like effects produced by the delta-opioid agonist SNC80 in rats. Psychopharmacology 182, 588-596 (2005).
39. Haffmans, J. and Dzoljic, M.R. Differential epileptogenic potentials of selective μ and δ opiate receptor agonists. J. Neural Transm. 57, 1-11 (1983).
40. Stutzmann, J.M., Böhme, G.A., Roques, B.P., Blanchard, J.C. Differential electrographic patterns for specific μ- and δ-opioid peptides in rats. Eur. J. Pharmacol. 123, 53-59 (1986).
41. Walker, G.E. and Yaksh, T.L. Studies on the effects of intrathalamically injected DADL and morphine on nociceptive thresholds and electroencephalographic activity: A thalamic δ receptor syndrome. Brain Res. 383, 1-14 (1986).
42. Snead, O.C., III. Opiate-induced seizures: A study of μ and δ specific mechanisms. Exp. Neurol. 93, 348-358 (1986).
43. De Sarro, G.B., Marra, R., Spagnolo, C., and Nisticò, G. Delta opioid receptors mediate seizures produced by intrahippocampal injection of ala-deltorphin in rats. Funct. Neurol. 3, 235-238 (1992).
44. Chipkin, R.E. and Coffin, V.L. Analgesic and acute central nervous system side effects of the intravenously administered enkephalinase inhibitor SCH 32615. Pharmacol. Biochem. Behav. 38, 21-27 (1991).
45. Sackheim, H.A. The anticonvulsant hypothesis of the mechanisms of action of ECT: Current status. J. ECT 15, 5-26 (1999). This is an interesting review of some aspects of electroconvulsive therapy used in determining clinical efficacy.
46. Settle, E.C., Jr. Bupropion sustained release: Side effect profile. J. Clin. Psychiatry 59 (Suppl 4), 32-36 (1998).
47. Shepherd, G. Adverse effects associated with extra doses of bupropion. Pharmacotherapy 25, 1378-1382 (2005).
48. Prueter, C. and Norra, C. Mood disorders and their treatment in patients with epilepsy. J. Neuropsychiatry Clin. Neurosci. 17, 20-28 (2005).
49. Montgomery, S.A. Antidepressant and seizures: Emphasis on newer agents and clinical implications. Int. J. Clin. Pract. 59, 1435-1440 (2005).
50. Jutkiewicz, E.M., Chang, K.J., Rice, K.C., Woods, J.H. Characterization of a novel nonpeptide delta-opioid agonist analog DPI287 with antidepressant-like activity. Experimental Biology meeting abstracts. FASEB J. 19, Abstract # 874.4 (2005).
51. Detke, M.J., Rickels, M., and Lucki, I. Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology 121, 66-72 (1995). This is the first report in the literature of a modified forced swim test that allowed for the separation of serotonin- and norepinephrine-related behaviors.
52. Spina, L., Longoni, R., Mulas, A., Chang, K.-J., and Di Chiara, G. Dopamine-dependent behavioural stimulation by non-peptide delta opioids BW373U86 and SNC 80: 1. Locomotion, rearing and stereotypies in intact rats. Behav. Pharmacol. 9, 1-8 (1998).
53. Hudzik, T.J., Howell, A., Payza, K., and Cross, A.J. Antiparkinsonian potential of δ-opioid receptor agonists. Eur. J. Pharmacol. 396, 101-107 (2000). This is the first report of the antiparkinsonian effects of nonpeptidic delta-opioid agonists in rodents.
54. Hille, C.J., Fox, S.H., Maneuf, Y.P., Crossman, A.R., Brotchie, J.M. Antparkinsonian action of a δ-opioid agonist in rodent and primate models of Parkinson's disease. Exp. Neurol. 172, 189-198 (2001).
55. Negus, S.S., Gatch, M.B., Mello, N.K., Zhang, X., Rice, K. Behavioral effects of the delta-selective opioid agonist SNC80 and related compounds in rhesus monkeys. J. Pharmacol. Exp. Ther. 286, 362-375 (1998).
56. Longoni, R., Cadoni, C., Mulas, A., Di Chiara, G., and Spina, L. Dopamine-dependent behavioural stimulation by non-peptide delta opioids BW373U86 and SNC 80: 2. Place-preference and brain microdialysis studies in rats. Behav. Pharmacol. 9, 9-14 (1998). This is the only report in the literature of the effects of nonpeptidic delta-opioid agonists on dopamine release in the rat microdialysis studies.
57. Russo-Neustadt, A.A. and Chen, M.J. Brain-derived neurotrophic factor and antidepressant activity. Curr. Pharm. Des. 11, 1495-1510 (2005). This is a good overview of the role of BDNF in depression and in the actions of antidepressants.
58. Malberg, J.E. and Blendy, J.A. Antidepressant action: To the nucleus and beyond. Trends Pharmacol. Sci. 26, 631-638 (2005). This is a useful overview of the proposed mechanisms of action of known antidepressants.
59. Torregrossa, M.M., Folk, J.E., Rice, K.C., Watson, S.J., and Woods, J.H. Chronic administration of the delta opioid receptor agonist (+)BW373U86 and antidepressants on behavior in the forced swim test and BDNF mRNA expression in rats. Psychopharmacology 183, 31-40 (2005).
60. Narita, M., Kuzumaki, N., Miyatake, M., Sato, F., Wachi, H., Seyama, Y., and Suzuki, T. Role of d-opioid receptor function in neurogenesis and neuroprotection. J. Neurochem. 97, 1494-1505 (2006).
61. Tsao, L.-I., Ladenheim, B., Andrews, A.M., Chiueh, C.C., Cadet, J.L., and Su, T.-P. Delta opioid peptide [d-Ala2, d -leu5]enkephalin blocks the long-term loss of dopamine transporters induced by multiple administrations of methamphetamine: Involvement of opioid receptors and reactive oxygen species. J. Pharmacol. Exp. Ther. 287, 322-331 (1998).
62. Borlongan, C.V., Su, T.-P., and Wang, Y. Treatment with delta opioid peptide enhances in vitro and in vivo survival of rat dopaminergic neurons. Neuropharmacology 11, 923-926 (2000).
63. Zhang, J., Gibney, G.T., Zhao, P., and Xia, Y. Neuroprotective role of delta-opioid receptors in cortical neurons. Am. J. Physiol. Cell Physiol. 282, C1225-C1234 (2002).
64. Narita, M., Kuzumaki, N., Narita, M. et al. Age-related emotionality is associated with cortical δ-opioid receptor dysfunction-dependent astrogliosis. Neuroscience 137, 1359-1367 (2006). This paper described for the first time that nonpeptidic delta-opioid agonists actually promote neurogenesis.
65. Nielsen, J.A., Shannon, N.J., Bero, L., and Moore, K.E. Effects of acute and chronic bupropion on locomotor activity and dopaminergic neurons. Pharmacol. Biochem. Behav. 24, 795-799 (1986).
66. Zarrindast, M.R. and Hosseini-Nia, T. Anorectic and behavioural effects of bupropion. Neuroprotective role of δ-opioid receptors in cortical neurons. Am. J. Physiol. Cell Physiol. 282, C1225-C1234 (1988).
67. Ninan, P.T., Hassman, H.A., Glass, S.J., and McManus, F.C. Adjunctive modafinil at initiation of treatment with a selective serotonin reuptake inhibitor enhances the degree and onset of therapeutic effects in patients with major depressive disorder. J. Clin. Psychiatry 65, 414-420 (2004).
68. Fava, M. Augmentation and combination strategies in treatment-resistant depression. J. Clin. Psychiatry 62 (Suppl 18), 4-11 (2001). This is a useful overview of the augmentation strategies used in treating depression.
69. Stahl, S.M., Zhang, L., Damatarca, C., and Grady, M. Brain circuits determine destiny in depression: A novel approach to the psychopharmacology of wakefulness, fatigue, and executive dysfunction in major depressive disorder. J. Clin. Psychiatry 64 (Suppl 14), 6-17 (2003). This review provides an excellent overview of the various aspects of depression and the neurobiology that may be involved.